ANIK Stock Overview A joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. More details
Rewards Risk Analysis No risks detected for ANIK from our risk checks.
See All Risk Checks Capture your thoughts, links and company narrative
Anika Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Anika Therapeutics Historical stock prices Current Share Price US$16.31 52 Week High US$29.12 52 Week Low US$15.83 Beta 0.90 1 Month Change -5.06% 3 Month Change -36.04% 1 Year Change -30.00% 3 Year Change -57.07% 5 Year Change -69.13% Change since IPO 366.00%
Recent News & Updates See more updates
Improved Revenues Required Before Anika Therapeutics, Inc. (NASDAQ:ANIK) Shares Find Their Feet Dec 19 Anika Therapeutics, Inc. Reports Impairment Charges for the Third Quarter Ended September 30, 2024 Nov 01
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Nov 01
Anika Therapeutics, Inc. to Report Q3, 2024 Results on Oct 31, 2024 Oct 18
Price target increased by 14% to US$34.50 Sep 16
Second quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat Aug 09
Anika Therapeutics, Inc. Affirms Earnings Guidance for the Fiscal Year 2024 Aug 09
Anika Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Jul 25
Anika Therapeutics, Inc. Announces Full Market Release of the Integrity Implant System, a Regenerative Hyaluronic Acid-Based Scaffold for Rotator Cuff and Other Tendon Repairs Jul 11
Anika Therapeutics, Inc., Annual General Meeting, Jul 09, 2024 Jun 13 Anika Therapeutics, Inc. (NasdaqGS:ANIK) announces an Equity Buyback for $40 million worth of its shares. May 30
Anika Therapeutics, Inc. Announces Board Changes May 29
First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind May 09 Anika Therapeutics, Inc. Announces CFO Changes
Anika Therapeutics, Inc. to Report Q1, 2024 Results on May 08, 2024 Apr 20
President exercised options and sold US$717k worth of stock Mar 15
Anika Therapeutics, Inc. Provides Earnings Guidance for the Fiscal Year 2024 Mar 14
Anika Therapeutics, Inc. to Report Q4, 2023 Results on Mar 13, 2024 Feb 28
Is There An Opportunity With Anika Therapeutics, Inc.'s (NASDAQ:ANIK) 44% Undervaluation? Jan 30
Anika Therapeutics, Inc. Announces First Surgeries Performed Using the Integrity Implant System Nov 29
Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 03
Anika Therapeutics, Inc. Revises Revenue Guidance for the Fiscal Year 2023 Nov 03
Anika Therapeutics, Inc. to Report Q3, 2023 Results on Nov 02, 2023 Oct 11
Anika Therapeutics, Inc. Receives 510(k) Clearance for Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Patch System for Augmentation of Rotator Cuff Repairs Aug 18
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Aug 09
Anika Therapeutics, Inc. Revises Revenue Guidance for the Fiscal Year 2023 Aug 09
Companies Like Anika Therapeutics (NASDAQ:ANIK) Can Afford To Invest In Growth Aug 03
Anika Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023 Jul 23
Anika Therapeutics, Inc. announces Completed Enrollment of the Pivotal Phase III Clinical Study for Hyalofast (Hyalofast 15-01) on Its Path to Achieving FDA Approval in the United States May 31
Consensus EPS estimates fall by 39% May 16
First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind May 11
Anika Therapeutics, Inc. Provides Earnings Guidance for the Year 2023 May 10
President exercised options and sold US$345k worth of stock Mar 15
Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Mar 07
Consensus forecasts updated Nov 16
Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 09
Anika Therapeutics, Inc. Provides Revenue Guidance for the Fiscal Year 2022 Nov 09
Anika Therapeutics, Inc.’s Cingal® Successfully Achieves Primary Endpoint in Third Phase III Study Nov 02
Anika Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022 Oct 26
Anika Announces First Surgeries Performed Using the X-Twist Fixation System and Commences Limited Market Release Sep 13
Second quarter 2022 earnings: EPS and revenues exceed analyst expectations Aug 04
Anika Therapeutics, Inc. to Report Q2, 2022 Results on Aug 03, 2022 Jul 13
Anika Receives FDA 510(k) Clearance for the X-Twist Knotless Fixation System, Expanding its Sports Medicine Soft Tissue Portfolio May 21
First quarter 2022 earnings: EPS and revenues exceed analyst expectations May 06
Anika Therapeutics, Inc. Provides Revenue Guidance for the Year 2022 May 06
Price target decreased to US$40.50 Apr 27
Anika Therapeutics, Inc. to Report Q1, 2022 Results on May 05, 2022 Apr 08
President recently bought US$207k worth of stock Mar 15
Anika Therapeutics: New Share Price Low May Imply New Upside Opportunity Mar 11 Anika Therapeutics, Inc. Provides Revenue Guidance for Fiscal 2022 Mar 10
Price target decreased to US$43.75 Mar 09
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Mar 09
Insider exercised options and sold US$55k worth of stock Mar 01
Anika Therapeutics, Inc. to Report Q4, 2021 Results on Mar 08, 2022 Feb 09
Third quarter 2021 earnings released: EPS US$0.039 (vs US$0.45 loss in 3Q 2020) Nov 06
Anika Therapeutics, Inc. Receives an Additional 510(K) Clearance by the Fda for Tactoset® Injectable Bone Substitute Sep 15
Second quarter 2021 earnings released: EPS US$0.45 (vs US$0.54 loss in 2Q 2020) Aug 08
Anika Therapeutics, Inc. Revises Earnings Guidance for the Year 2021 Aug 06
Anika Therapeutics, Inc. Announces First Anika Wristmotion Total Wrist Arthroplasty Surgery Performed Jul 02
Are Investors Undervaluing Anika Therapeutics, Inc. (NASDAQ:ANIK) By 48%? Jun 25
Independent Director Joseph Bower has left the company Jun 22
Anika Therapeutics, Inc. Provides Earnings Guidance for the Year 2021 Jun 04
Anika Therapeutics (ANIK) Presents At UBS Global Healthcare Virtual Conference - Slideshow May 28
Independent Director recently sold US$85k worth of stock May 16
First quarter 2021 earnings released: EPS US$0.20 (vs US$0.41 in 1Q 2020) May 08
Anika Therapeutics, Inc. Provides Earnings Guidance for the Year 2021 May 07
Anika Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation May 07
How Much Are Anika Therapeutics, Inc. (NASDAQ:ANIK) Insiders Taking Off The Table? Mar 16
Full year 2020 earnings released: US$1.69 loss per share (vs US$1.93 profit in FY 2019) Mar 06
Earnings beat expectations, revenue disappoints Mar 06
Insider exercised options and sold US$64k worth of stock Mar 03
New 90-day low: US$35.54 Feb 19
Anika Therapeutics, Inc. to Report Q4, 2020 Results on Mar 04, 2021 Feb 10
Anika Therapeutics (NASDAQ:ANIK) Seems To Use Debt Quite Sensibly Feb 09
An Intrinsic Calculation For Anika Therapeutics, Inc. (NASDAQ:ANIK) Suggests It's 32% Undervalued Jan 13
New 90-day high: US$45.26 Jan 01
If You Had Bought Anika Therapeutics' (NASDAQ:ANIK) Shares A Year Ago You Would Be Down 21% Dec 18
New 90-day high: US$39.27 Dec 16
New 90-day high: US$39.04 Nov 25
Independent Director recently sold US$127k worth of stock Nov 15
Anika Therapeutics, Inc. 2020 Q3 - Results - Earnings Call Presentation Nov 06
Third quarter 2020 earnings released: US$0.45 loss per share Nov 06
Revenue and earnings beat expectations Nov 06
Price target lowered to US$51.00 Oct 31
Anika Therapeutics, Inc. Suspends Financial Guidance for the Full Year 2020 Sep 12
Price target lowered to US$51.00 Aug 25
First half earnings released Aug 10 Shareholder Returns ANIK US Biotechs US Market 7D -5.0% -5.6% -3.5% 1Y -30.0% -1.5% 22.1%
See full shareholder returns
Return vs Industry: ANIK underperformed the US Biotechs industry which returned -1.5% over the past year.
Return vs Market: ANIK underperformed the US Market which returned 22.1% over the past year.
Price Volatility Is ANIK's price volatile compared to industry and market? ANIK volatility ANIK Average Weekly Movement 9.5% Biotechs Industry Average Movement 10.7% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.0% 10% least volatile stocks in US Market 3.1%
Stable Share Price: ANIK has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ANIK's weekly volatility (9%) has been stable over the past year.
About the Company Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief.
Show more Anika Therapeutics, Inc. Fundamentals Summary How do Anika Therapeutics's earnings and revenue compare to its market cap? ANIK fundamental statistics Market cap US$239.16m Earnings (TTM ) -US$97.52m Revenue (TTM ) US$164.17m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) ANIK income statement (TTM ) Revenue US$164.17m Cost of Revenue US$83.93m Gross Profit US$80.23m Other Expenses US$177.75m Earnings -US$97.52m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -6.66 Gross Margin 48.87% Net Profit Margin -59.40% Debt/Equity Ratio 0%
How did ANIK perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/20 22:59 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Anika Therapeutics, Inc. is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Michael Petusky Barrington Research Associates, Inc. Mark Landy Northland Capital Markets James Sidoti Sidoti & Company, LLC
Show 3 more analysts 
